Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

researchers have found that the immune response in our lungs depends on the physical pressure experienced by lung cells. When […] CRISPR study finds new cancer immunotherapy target A new Yale-led ...

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

Scientists at the Garvan Institute of Medical Research have discovered that certain gene variations associated with leukemia ...

The genetically modified animal model could lead to new treatments for the global disease Lauren Rust, Ph.D., assistant staff ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...